Latest news
Neoadjuvant Sacituzumab Govitecan in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer - Brigida Maiorano - UroTodayUroToday · Thu, 06 Aug 2026 00:32:57 GMTHealth Canada Approves KEYTRUDA® for the treatment of adult patients with muscle invasive bladder cancer who are ineligible for cisplatin containing chemotherapy, in combination with enfortumab vedotin, as neoadjuvant treatment and then continued after - Yahoo FinanceYahoo Finance · Wed, 05 Aug 2026 15:00:00 GMT